Skip to main content

Secondary Prevention clinical trials at UC Health
1 research study open to new patients

  • Safety of Dabigatran Etexilate in Blood Clot Prevention in Children

    open to eligible people ages up to 18 years

    This open-label, single arm prospective cohort study will assess the safety of dabigatran etexilate in secondary prevention of venous thromboembolism in paediatric patients. Children from 0 to less than 18 years of age will be eligible to participate.

    at UC Davis

Last updated: